• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Cancer Chemotherapy Sodium Bicarbonate Severe Tissue Damage Drug Monograph Documentation Sheet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    De Vita VT, Carbone PP, Owens AH, et al: Clinical trials with 1,3-bis(2chloroethyl)- 1-nitrosourea, NSC-409962. Cancer Res 25: 1876–1881, 1965.PubMedGoogle Scholar
  2. [2]
    Marsh JC, DeConti RC, Hubbard SP: Treatment of Hodgkin’s disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC409962). Cancer Chemother Rep 55: 599–606, 1971.PubMedGoogle Scholar
  3. [3]
    Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.PubMedCrossRefGoogle Scholar
  4. [4]
    Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.PubMedGoogle Scholar
  5. [5]
    Colvin M, Hartner J, Summerfield M: Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 37: 677–678, 1980.PubMedGoogle Scholar
  6. [6]
    Laskar PA, Ayres JW: Degradation of carmustine in aqueous media. J Pharm Sci 66: 1073–1076, 1977.PubMedCrossRefGoogle Scholar
  7. [7]
    Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.Google Scholar

Secondary literature

  1. [8]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  2. [9]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  3. [10]
    Allwood M: Chemotherapeutic agents: carmustine. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 199–202, 1997.Google Scholar
  4. [11]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 109–118, 1994.Google Scholar
  5. [12]
    Dorr RT, Von Hoff DD: Drug monographs: carmustine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 267–275, 1994.Google Scholar
  6. [13]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  7. [14]
    Summary of product characteristics Carmubris (Austria), Bristol-Myers Squibb, July 1996.Google Scholar
  8. [15]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154160, 1992.Google Scholar
  9. [16]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  10. [17]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  11. [18]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  12. [19]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  13. [20]
    Donislawski S, Gain M, Meyer-Jürshof A, et al: Carmustin: Behandlung von Paravasaten. In: Donislawski S, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Vol 2: 21, 1994.Google Scholar
  14. [21]
    Holmes BC: Administration of cancer chemotherapy agents. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 57–94, 1994.Google Scholar
  15. [22]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  16. [23]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations